Brokers Offer Predictions for OS Therapies Q3 Earnings

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Stock analysts at Brookline Capital Markets increased their Q3 2026 earnings per share estimates for OS Therapies in a research report issued on Tuesday, September 8th. Brookline Capital Markets analyst K. Raja now anticipates that the company will post earnings per share of ($0.16) for the quarter, up from their previous forecast of ($0.19). The consensus estimate for OS Therapies’ current full-year earnings is ($0.77) per share. Brookline Capital Markets also issued estimates for OS Therapies’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.10) EPS, FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.24 EPS.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter.

A number of other analysts have also recently weighed in on the stock. Lake Street Capital lowered their target price on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Roth Capital initiated coverage on OS Therapies in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 price objective on the stock. Finally, Zacks Research upgraded OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $13.33.

OS Therapies Stock Performance

NYSEAMERICAN:OSTX opened at $1.82 on Friday. The company has a 50-day moving average of $1.62 and a 200-day moving average of $1.62. OS Therapies has a 52 week low of $1.15 and a 52 week high of $2.35. The company has a market capitalization of $83.96 million, a price-to-earnings ratio of -1.67 and a beta of -0.68.

Institutional Trading of OS Therapies

Several large investors have recently added to or reduced their stakes in OSTX. Susquehanna International Group LLP acquired a new stake in shares of OS Therapies in the third quarter valued at $29,000. Jane Street Group LLC acquired a new position in OS Therapies during the 4th quarter worth about $39,000. Mercer Global Advisors Inc. ADV acquired a new position in OS Therapies during the 3rd quarter worth about $40,000. AXQ Capital LP bought a new stake in OS Therapies during the 2nd quarter worth about $47,000. Finally, Bridgeway Capital Management LLC bought a new stake in OS Therapies during the 2nd quarter worth about $47,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.